ABSTRACT
After the meeting held by the Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC) back in October 2021, changes were suggested to the Spanish standard series patch testing. Hydroxyethyl methacrylate (2% pet.), textile dye mixt (6.6% pet.), linalool hydroperoxide (1% pet.), and limonene hydroperoxide (0.3% pet.) were, then, added to the series that agreed upon in 2016. Ethyldiamine and phenoxyethanol were excluded. Methyldibromoglutaronitrile, the mixture of sesquiterpene lactones, and hydroxyisohexyl 3-cyclohexene (Lyral) were alo added to the extended Spanish series of 2022.
Subject(s)
Dermatitis, Allergic Contact , Patch Tests , Humans , Spain , Dermatitis, Allergic Contact/diagnosis , Dermatitis, Allergic Contact/etiology , Allergens/adverse effectsSubject(s)
Anti-Allergic Agents , Chronic Urticaria , Histamine Antagonists , Omalizumab , Humans , Omalizumab/therapeutic use , Chronic Urticaria/drug therapy , Female , Anti-Allergic Agents/therapeutic use , Male , Adult , Middle Aged , Histamine Antagonists/therapeutic use , Drug Therapy, CombinationSubject(s)
Urticaria , Humans , Urticaria/diagnosis , Urticaria/etiology , Chronic Inducible UrticariaSubject(s)
Adult , History, 21st Century , Urticaria , Seawater/adverse effects , Urticaria/diagnosis , Urticaria/etiology , Urticaria/pathology , Skin TestsABSTRACT
La urticaria es un motivo frecuente de consulta en Atención Primaria (AP); sin embargo, el correcto abordaje de esta enfermedad resulta controvertido y con frecuencia no está bien establecido. Por esta razón, se necesita esclarecer sus causas y desarrollar protocolos de tratamiento para mejorar el manejo de la urticaria en AP. Con este objetivo se ha realizado este trabajo. Un grupo de expertos en AP y dermatología, con experiencia en el tratamiento de la urticaria, han revisado las principales guías y publicaciones en urticaria con motivo de desarrollar recomendaciones claras e interdisciplinares sobre el manejo de la urticaria en AP. En este artículo presentamos nuestras recomendaciones basadas en el consenso de expertos, incluyendo algoritmos de diagnóstico y tratamiento simples y prácticos. Estas guías pueden ayudar a optimizar el manejo del paciente con urticaria, incrementar su calidad de vida y reducir los costes socioeconómicos asociados
Urticaria is a common cause for patient consultations in Primary Care (PC). However, the optimal approach to managing urticaria in PC is controversial and not well-established. For this reason, there is a clear need to clarify the causes of urticaria and to develop treatment protocols to improve urticaria management in the PC setting. The present work has been developed with this objective. A group of experts in PC and dermatology, with specific expertise in treating urticaria, have reviewed the main clinical guidelines and publications on urticaria in order to develop clear, interdisciplinary recommendations on managing urticaria. In this article, consensus-based recommendations are presented that include simple, practical diagnostic, and treatment algorithms. These guidelines will help to optimise the management of patients with urticaria, increasing their quality of life and reducing the socioeconomic costs associated with this illness
Subject(s)
Humans , Urticaria/diagnosis , Urticaria/drug therapy , Histamine Antagonists/therapeutic use , Dermatitis, Contact/diagnosis , Hypersensitivity/diagnosis , Hypersensitivity, Immediate/diagnosis , Primary Health Care/methods , Chronic Disease/therapy , Pruritus/diagnosis , Quality of Life/psychology , Sickness Impact Profile , Dermatitis, Contact/drug therapy , Hypersensitivity/drug therapy , Hypersensitivity, Immediate/drug therapyABSTRACT
No disponible
Subject(s)
Humans , Male , Aged , Psoriasis/drug therapy , Etanercept/administration & dosage , Kidney Transplantation/adverse effects , Immunosuppressive Agents/therapeutic use , Biological Products/therapeutic useABSTRACT
Urticaria is a common cause for patient consultations in Primary Care (PC). However, the optimal approach to managing urticaria in PC is controversial and not well-established. For this reason, there is a clear need to clarify the causes of urticaria and to develop treatment protocols to improve urticaria management in the PC setting. The present work has been developed with this objective. A group of experts in PC and dermatology, with specific expertise in treating urticaria, have reviewed the main clinical guidelines and publications on urticaria in order to develop clear, interdisciplinary recommendations on managing urticaria. In this article, consensus-based recommendations are presented that include simple, practical diagnostic, and treatment algorithms. These guidelines will help to optimise the management of patients with urticaria, increasing their quality of life and reducing the socioeconomic costs associated with this illness.
Subject(s)
Urticaria , Chronic Disease , Consensus , Humans , Primary Health Care , Quality of Life , Referral and ConsultationABSTRACT
No disponible
Subject(s)
Humans , Female , Middle Aged , Omalizumab/therapeutic use , Anti-Allergic Agents/therapeutic use , Urticaria/drug therapy , Vasculitis, Leukocytoclastic, Cutaneous/drug therapy , Treatment Outcome , SyndromeABSTRACT
No disponible
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Dermatitis, Contact/diagnosis , Piper nigrum/adverse effects , Vitiligo/drug therapy , Dermatitis, Contact/etiology , Patch Tests/methodsABSTRACT
La dermatitis atópica (DA) se ha convertido en un problema de salud en nuestro medio debido al aumento de su prevalencia, la alteración de la calidad de vida, los gastos que ocasiona y su implicación en la progresión a otras enfermedades atópicas. Además no tiene una cura definitiva, por lo que sería interesante la aplicación de medidas preventivas. En este artículo se revisan los últimos avances implicados en su prevención, tanto primaria (disminución de incidencia), como secundaria (disminución de morbilidad, evitar la progresión de la marcha atópica). Se abordan las diversas estrategias implicadas, entre las que se encuentran la modificación del sistema inmune mediante exposición microbiana, la inducción de tolerancia inmunológica por exposición antigénica y la restauración de la función barrera para frenar la marcha atópica. Estas medidas deberían ser conocidas por los dermatólogos para aplicarlas cuando sea posible, y poder informar adecuadamente a los pacientes y familiares, evitando actuaciones inadecuadas y/o erróneas
Atopic dermatitis has become a health problem in our setting due to its rising prevalence, impact on quality of life, associated costs, and role in the progression to other atopic diseases. Furthermore, atopic dermatitis has no definitive cure and therefore preventive measures are important. In this article, we review the latest advances in both primary prevention (reduction of the incidence of atopic dermatitis) and secondary prevention (reduction of associated morbidity and reduction of the atopic march). We analyze the different preventive strategies available, including modification of the immune system through microbial exposure, induction of immune tolerance through antigen exposure, and restoration of skin barrier function to halt the atopic march. Dermatologists need to be familiar with these strategies in order to apply them where necessary and to accurately inform patients and their relatives to prevent misguided or inappropriate actions
Subject(s)
Humans , Dermatitis, Atopic/prevention & control , Probiotics/therapeutic use , Prenatal Nutrition , Early Diagnosis , Patient Education as Topic , Evidence-Based Practice/methods , Endotoxins/adverse effectsABSTRACT
Atopic dermatitis has become a health problem in our setting due to its rising prevalence, impact on quality of life, associated costs, and role in the progression to other atopic diseases. Furthermore, atopic dermatitis has no definitive cure and therefore preventive measures are important. In this article, we review the latest advances in both primary prevention (reduction of the incidence of atopic dermatitis) and secondary prevention (reduction of associated morbidity and reduction of the atopic march). We analyze the different preventive strategies available, including modification of the immune system through microbial exposure, induction of immune tolerance through antigen exposure, and restoration of skin barrier function to halt the atopic march. Dermatologists need to be familiar with these strategies in order to apply them where necessary and to accurately inform patients and their relatives to prevent misguided or inappropriate actions.
Subject(s)
Dermatitis, Atopic/prevention & control , Animals , Animals, Domestic , Anti-Bacterial Agents/therapeutic use , Antigens/therapeutic use , Biological Therapy , Breast Feeding , Clinical Trials as Topic , Dermatitis, Atopic/diet therapy , Dermatitis, Atopic/etiology , Desensitization, Immunologic , Dust , Environmental Exposure , Evidence-Based Medicine , Helminthiasis/immunology , Humans , Immune Tolerance , Meta-Analysis as Topic , Prebiotics , Primary Prevention/methods , Probiotics , Secondary Prevention/methodsABSTRACT
No disponible
Subject(s)
Humans , Female , Adult , Exanthema/chemically induced , Cyclooxygenase 2 Inhibitors/adverse effects , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Patch TestsABSTRACT
No disponible
